Upstream Bio (NASDAQ:UPB – Get Free Report) is projected to release its earnings data before the market opens on Thursday, February 6th. Analysts expect Upstream Bio to post earnings of ($0.62) per share for the quarter.
Upstream Bio (NASDAQ:UPB – Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($6.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($6.38). The firm had revenue of $0.61 million during the quarter, compared to analyst estimates of $0.83 million. On average, analysts expect Upstream Bio to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Upstream Bio Trading Down 7.8 %
NASDAQ UPB opened at $9.93 on Tuesday. The stock’s 50-day simple moving average is $16.57. Upstream Bio has a twelve month low of $9.29 and a twelve month high of $29.46.
Analysts Set New Price Targets
Read Our Latest Stock Analysis on UPB
About Upstream Bio
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Further Reading
- Five stocks we like better than Upstream Bio
- How to Use High Beta Stocks to Maximize Your Investing Profits
- How to Invest in Small Cap Stocks
- What is the S&P 500 and How It is Distinct from Other Indexes
- These Are the Dividend Stocks Insiders Bought in January
- What Investors Need to Know to Beat the Market
- How the ‘No Buy’ Trend of 2025 Is Boosting These 3 Stocks
Receive News & Ratings for Upstream Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Upstream Bio and related companies with MarketBeat.com's FREE daily email newsletter.
